Aktis Oncology, Inc. - Common stock (AKTS)
AKTS moved a median of -1.22% 30 minutes after news, and -1.68% by the close. How AKTS actually reacts to news — the realized, point-in-time move the market made, measured across 131 labeled events over the last three years with zero look-ahead.
AKTS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.66% | 34% | 129 |
| 30-min | -1.22% | 39% | 129 |
| 60-min | -1.35% | 44% | 129 |
| to close | -1.68% | 45% | 129 |
| Middle 50% of AKTS reactions | -5.18% to +1.37% |
|---|---|
| Median reaction (30-min) | -1.22% |
| Measured reactions | 131 |
Half of all Aktis Oncology, Inc. - Common stock news events land between -5.18% and +1.37% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AKTS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AKTS's baseline. Nothing else.
Recent AKTS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 | Press release | GlobeNewswire | +0.72% | -4.58% | |
| Aktis Oncology to Present at Upcoming September Investor Conferences | Press release | GlobeNewswire | +0.90% | -5.91% | |
| Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 | Press release | GlobeNewswire | -1.54% | +4.00% | |
| Aktis Oncology to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -3.03% | +1.54% | |
| Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors | Press release | GlobeNewswire | -1.16% | +4.52% | |
| Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 | Press release | GlobeNewswire | +0.00% | +7.70% | |
| Aktis Oncology to Present at the BofA Securities Health Care Conference | Press release | GlobeNewswire | +1.56% | +0.91% | |
| Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Press release | GlobeNewswire | +0.00% | +2.26% | |
| Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB | Press release | Business Wire | +0.62% | -1.35% | |
| Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Press release | GlobeNewswire | +0.82% | +5.97% | |
| Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors | Press release | GlobeNewswire | -0.60% | +2.20% | |
| Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results | Press release | GlobeNewswire | -0.76% | +3.95% | |
| Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate | Press release | GlobeNewswire | -1.59% | +2.35% | |
| Aktis Oncology to Present at Upcoming March Investor Conferences | Press release | GlobeNewswire | +0.68% | -4.69% | |
| Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -1.00% | -7.38% | |
| Form NT 10-Q Akoustis Technologies, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | — | — | |
| Form 8-K Akoustis Technologies, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process | Press release | Business Wire | +2.22% | -9.11% | |
| Form 8-K Akoustis Technologies, For: Dec 15 | SEC filing · Form 8-K | SEC EDGAR | -8.50% | -7.00% | |
| Form 8-K Akoustis Technologies, For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | -9.07% | |
| Form DEFA14A Akoustis Technologies, | SEC filing · Form DEFA14A | SEC EDGAR | -2.00% | -9.07% | |
| Form 8-K Akoustis Technologies, For: Nov 29 | SEC filing · Form 8-K | SEC EDGAR | +4.47% | -2.92% | |
| Form 8-K Akoustis Technologies, For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | +4.88% | +10.85% | |
| Form 8-K Akoustis Technologies, For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | +2.65% | |
| Form DEFA14A Akoustis Technologies, | SEC filing · Form DEFA14A | SEC EDGAR | -0.10% | +2.65% | |
| Form 10-Q Akoustis Technologies, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.00% | +7.00% | |
| Form 8-K Akoustis Technologies, For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -5.57% | -6.96% | |
| Form DEFA14A Akoustis Technologies, | SEC filing · Form DEFA14A | SEC EDGAR | -5.57% | -6.96% | |
| Form 8-K Akoustis Technologies, For: Oct 11 | SEC filing · Form 8-K | SEC EDGAR | -3.00% | -4.71% | |
| Form 8-K Akoustis Technologies, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | -3.03% | +7.73% | |
| Form DEFA14A Akoustis Technologies, | SEC filing · Form DEFA14A | SEC EDGAR | -3.03% | +7.73% | |
| Form 10-K/A Akoustis Technologies, For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -2.60% | -3.12% | |
| Form 8-K Akoustis Technologies, For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -2.60% | -3.12% | |
| Form 10-K Akoustis Technologies, For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -1.75% | +11.73% | |
| Form ARS Akoustis Technologies, For: Jun 30 | SEC filing · Form ARS | SEC EDGAR | -1.75% | +11.73% | |
| Form DEF 14A Akoustis Technologies, For: Nov 21 | SEC filing · Form DEF | SEC EDGAR | -1.75% | +11.73% | |
| Form DEFA14A Akoustis Technologies, | SEC filing · Form DEFA14A | SEC EDGAR | -1.75% | +11.73% | |
| Form NT 10-K Akoustis Technologies, For: Jun 30 | SEC filing · Form NT | SEC EDGAR | -2.23% | -15.20% | |
| Form 8-K Akoustis Technologies, For: Sep 20 | SEC filing · Form 8-K | SEC EDGAR | -5.43% | -2.29% | |
| Form PRE 14A Akoustis Technologies, For: Sep 17 | SEC filing · Form PRE | SEC EDGAR | -4.21% | -0.34% | |
| Form 8-K Akoustis Technologies, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.33% | +1.83% | |
| Form 8-K Akoustis Technologies, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +3.49% | +2.66% | |
| Form 8-K Akoustis Technologies, For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -6.70% | -6.02% | |
| Akoustis Receives an Additional Purchase Order for $13 Million XBAW® Filters from Existing Tier-1 Customer | Press release | GlobeNewswire | -14.06% | -23.49% | |
| Akoustis Announces Leadership Transition | Press release | GlobeNewswire | -0.81% | -4.41% | |
| Form 8-K Akoustis Technologies, For: Aug 02 | SEC filing · Form 8-K | SEC EDGAR | -1.88% | -9.88% | |
| Form 8-K Akoustis Technologies, For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +1.31% | |
| Akoustis Secures $8 Million in Volume XBAW® Orders with Tier-1 Customer | Press release | GlobeNewswire | -5.06% | -19.62% | |
| Akoustis Receives $2 Million in Volume Orders for Wi-Fi 7 Program from Tier-1 Carrier | Press release | GlobeNewswire | -6.75% | +0.27% | |
| Form 8-K Akoustis Technologies, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -1.37% | +1.37% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AKTS section they belong to.
Where else AKTS is measured.
AKTS earnings → · Analyst actions → · SEC filings →
Other Technology names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Frequency Electronics, Inc. (FEIM) | 132 | -0.06% | 45% |
| THIN FILM ELECTRONICS ASA AME (TFECY) | 132 | 0.00% | 13% |
| GREENE CONCEPTS INC NEW (INKW) | 129 | 0.00% | 36% |
| LGL Group, Inc. (The) (LGL) | 129 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Technology names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aktis Oncology, Inc. - Common stock's median reaction calculated?
Every labeled AKTS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 131 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of AKTS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AKTS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.